6 January 2026
Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps GSK plc (LSE/NYSE: GSK) today announced the approval of Exdensur (depemokimab) by Japan’s Ministry…
Prudential announces launch of USD 1.2 billion share buyback programme Prudential plc (the “Company”) announces that it will commence a buyback programme of its…
22 December 2025
Watkin Jones plc (‘Watkin Jones’ or the ‘Group’) Development Partnership for 294-unit hotel in Wimbledon Watkin Jones, the UK’s leading developer and manager of…
LONDONMETRIC PROPERTY PLC LONDONMETRIC TRANSACTS ON £91 MILLION OF INVESTMENT ACTIVITY LondonMetric Property Plc (“LondonMetric”) announces that it has sold £64.4 million of retail assets…
GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans GSK plc (LSE/NYSE: GSK)…
Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer Tenth Breakthrough Therapy Designation for AstraZeneca and…
Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer The LATIFY Phase III trial of ceralasertib in…
18 December 2025
HARWORTH GROUP PLC (‘Harworth’ or the ‘Group’ or the ‘Company’) Harworth secures 267,000 sq ft of I&L Investment Portfolio lettings, delivering £2.5m of annualised…